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1. Introduction 26,23-lactone isbiosynthesized from 25-OH-D3 by 
way of 23,25-(OH)2Ds to 23,25,26-(0H)aDa. 
A new metabolite of vitamin Da has been isolated 
from the plasma of chickens, rats and pigs and iden- 
tified as 25hydroxyvitamin Da-26,231actone (25OH- 
Ds-26,23Jactone) [l-3]. The stereochemical config- 
urations of natural 25OH-Da-26,23-lactone at the C-23 
and C-25 positions were determined to be 23(S) and 
25(R), respectively [4,5]. In [6] 25(5)26-dihydroxy 
vitamin Da (25@)26-(0H),Da) was reported as an 
intermediate in the biosynthesis of the 25-OH-D,-26, 
23-lactone. But, in [7] 25(S)26-(OH)?Ds was shown 
not to be a precursor of the 25.OH-Da-26,23-lactone 
[7]. The metabolic pathway to 25.OH-Ds-26,23-lactone 
from 25-hydroxyvitamin Da (25-OH-Da) was still 
unknown. 
2. Materials and methods 
2 .l . Compounds 
Two new metabolites of vitamin D3 have been 
isolated and identified, from the serum of rats given 
large doses of vitamin Da: 23,25-dihydroxyvitamin 
Da (23,25-(OH),D,) [8] and 23,25,26_trihydroxy- 
vitamin Da (23,25,26-(0H)aDa) [9]. The structure 
of the latter suggests a possible role as an intermediate 
in the biogenesis of the 25-OH-Da-26,23-lactone. 
The synthesis of 25-OH-Da, 24,25_dihydroxyvita- 
min Ds (24,25-(OH)aDa), lcr,25-dihydroxyvitamin 
Ds (lcr,25-(OH),Ds) and 25,26-(OH)2D3 were done 
in our laboratory as in [ 11,12].25-OH-Da-26,23-Lac- 
tone, 23,25-(OIQ2Ds and 23,25,26(OH)aDa were 
isolated from the serum of rats given large doses of 
vitamin Ds as in [ 5,8,9]. Four possible diastereoisomers 
of 25.OH-Da-26,23-lactone were synthesized asm [5]. 
Vitamin Da was obtained from Sigma Chemical Co. 
(Chicago IL). 
2.2. In vitro incubation of chick kidney homogenate 
with vitamin D3 metabolites 
The 25-OH-Da-26,23-lactone is produced in the 
kidney [3,6,10]; therefore we designed experiments 
in an attempt o generate this metabolite from vari- 
ous vitamin Da metabolites in vitro by using chick 
kidney homogenates. Here we show that 25-OH-Ds- 
Abbreviations: 25XIH-D,, 25-hydroxyvitamin D,; 25-OH-D,- 
26,23_lactone, 25llydroxyvitamin D,-26,234actone; 23,25- 
(OH),D,, 23,25dihydroxyvitamin D,; 24,25-(OH),D,, 24, 
25diiydroxyvitamin D,; 25,26-(OH),D,, 25,26diiydroxy- 
vitamin D,; lar,25-(OH),D,, la,25dihydroxyvitamin D,; 
23,25,26-(OH),D,, 23,25,26-trihydroxyvitamin D, 
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Six-week-old White Leghorn cockerels were fed 
first with the rachitogenic diet [ 131 and then with a 
diet containing 2.O% strontium and no calcium. They 
were given orally 2 pg la,25-(OH)2D, daily for 
10 days. The chicks were sacrificed, their kidneys 
were taken and 10% tissue homogenates in 0.25 M 
sucrose were prepared with a Potter-Elvehjem homog- 
enizer fitted with a Teflon pestle. To 24 ml homog- 
enate (13 mg protein/ml) in a 300 ml flask was added 
56 ml reaction mixture containing 30 mM Tris-HCl 
(PH 7.4), 3.6 mM MgC12, 50 mM sucrose and 20 mM 
sodium succinate as in [9,14]. The incubations were 
initiated by addition of 4 pg 25-OH-Da, 23,25- 
(OH),Ds, 23,25,26-(0H)sDa or 25(S)26-(OH)zD3 in
0.5 ml ethanol. The incubations were carried out at 
37°C for 60 mln with shaking. Chloroform:methanol 
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Fig.1. High-pressure liquid chromatographic profiles of the 24,25-(OH),D, fraction from Sephadex LH-20 column chromatography: 
(A) kidney homogenates incubated with 8 c(g 25-OH-D,; (B) kidney homogenates incubated with 8 ccg 23,25-(OH),D,; (C) kidney 
homogenatesincubated with 8 pg 23,25,26-(OH),D,; (D) kidney homogenatesincubated with 8 r.tg 25Q26_(OH),D,. Each capital 
letter ir&cates that the 24,25-(OH),D, fraction from Sephadex LH-20 column was subjected to high-pressure liquid chromatog- 
raphy with a Zorbax Sil column eluted with 9% isopropanol in n-hexane. Each small letter indicates that the putative 25_OH-D,- 
26,234actone in each capital letter was subjected to high-pressure liquid chromatography with a Zorbax Sil column eluted with 
1.5% methanol in dichloromethane. 
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(1 :l , 160 ml) was added to each flask to terminate 
the reaction. The 25-OH-Ds-26,23-lactone from incu- 
bation mixtures was separated and purified by 
Sephadex LH-20 column chromatography and hlgh- 
pressure liquid chromatography using a Zorbax Sil 
column (4.6 X 250 mm). 
2.3. Preparation and purification of 25-OH-D3-26,23- 
lactone by column chromatography 
The residue of chloroform extracts was dissolved 
in chloroform:n-hexane (65:35) and applied to a 
Sephadex LH-20 column (1.5 X 25 cm) packed and 
eluted with the same solvent. Sixty 4 ml fractions 
were collected. The 25-OH-D3 (tubes 9-l 5), the 
24,25(OH)2D3 (tubes 19-28)and the 25,26-(OH)*D3 
(tubes 3442) from the column separately pooled 
and concentrated. The 24,25-(OH)2D3 fraction from 
the Sephadex LH-20 column was then subjected to 
high-pressure liquid chromatography on a Hitachi 
Model 635 apparatus equipped with a 4.6 X 250 mm 
Zorbax Sll column eluted with 9% isopropanol in 
n-hexane at 1 ml/min. Ultraviolet absorbance was 
monitored at 264 mn by a Hitachi Model 200-10 
spectrophotometer. The putative 25-OH-D3-26,23- 
lactone fraction was further purified by high-pressure 
liquid chromatography using a Zorbax Sil column 
(4.6 X 250 mm) eluted with 1.5% methanol in dichlo- 
romethane. 
2.4. Spectroscopy 
Ultraviolet absorption spectra were recorded with 
a Hitachi Model 200-10 spectrophotometer. Mass 
spectra were determined with a Simadzu-I..KB mass 
spectrometer model 9000 in the direct probe inlet 
mode. The Fourier transform infrared (FT-IR) spectra 
were obtained by using a JEOL Model JIR4OX (Japan 
Electric Optical Laboratory Ltd.). 
3. Results 
The 25-OH-D3-26,23-lactone was eluted from 
Sephadex LH-20 column in a fraction corresponding 
to 24,25-(0H)2D3 [ 1,2], was separated from various 
vitamin D3 metabolites using high-pressure liquid 
chromatography with a Zorbax Sil column [l-3,10]. 
Kidney homogenates from la,25-(OH)?Ds-supple- 
mented chicks were incubated with 8 c(g 25-OH-DB, 
23,25-(OH)2D3, 23,25,26-(OH)3D3 or 25(S)26- 
(OH),D,. The chloroform extracts were dissolved in 
chloroform:n-hexane (65:35) and applied to a 
Sephadex LH-20 column and eluted with the same 
solvent. Fig.1 shows the high-pressure liquid chro- 
matographic profiles of 24,25-(OH)*D3 fraction from 
Sephadex LH-20 column of extracts of kidney homog- 
enates incubated with various vitamin D3 metabolites. 
A small amount of 25-OH-D3-26,23-lactone was pro- 
duced from 25-OH-D3 and 23,25-(OH)*D3 @g.lA,B). 
In contrast, large amounts of 25-OH-Ds-26,23-lactone 
were synthesized from 23,25,26-(OH)3D3, while no 
detectable amount of 25-OH-D3-26,23-lactone was 
found when 25(S)26-(OH)2D, was added to the incu- 
bation mixture as the substrate (fig.1 D). The 25-OH- 
Ds-26,23-lactone from 25-OH-D% 23,25-(OH)*Ds 
and 23,25,26-(OH)3D3 was identified by ultraviolet 
absorption, mass pectra nd Fourier transform 
infrared spectra s in [5]. Table 1 shows that the 
production of 25-OH-D3-26,23-lactone from chick 
kidney homogenates incubated with 8 ,ug various vita- 
min D3 metabolites. This result indicated that the 
production of 25-OH-Ds-26,23-lactone from 23,25, 
26(OH)3D3 was 35-times as much as that from 25- 
OH-Ds, whereas that from 23,25(OH)?D3 was 2.2- 
times more than that from 25-OH-Ds. Fig.2A illustrates 
that the 4 synthetic diastereoisomers of 25-OH-Ds- 
26,231actone could be separated into separate peaks 
by high-pressure liquid chromatography. The generated 
25-OH-D3-26,23-lactone from 23,25,26-(OH)sDJ 
comigrated with the 23(S)25@)25-OH-Ds-26,23-lac- 
tone (fig2B). Similarly, the 25-OH-D3-26,231actone 
generated from 25-OH-D3 and 23,25-(OH)2D3 comi- 
grated with the 23(S)25(R>25-OH-D3-26,23-lactone. 
Table 1 
Production of 25aH-D,-26,234actone from various vitamin 
D, metabolites 
Substrate 25_OH-D,-26,23_lactone produced 
(ng .4.8 g tissue-‘. h-l) 
25aH-D, 120 
23,25-(OH),D, 260 
23,25,2640H),D, 4200 
25026_(OH),D, undetectable 
A 10% kidney homogenate from lcr,25-(OH),D,-supple- 
mented chicks was incubated with 8 bg 25-OH-D,, 23,25- 
(OH),D,, 23,25,26-(OH),D, or 25(S)26-(OH),D, as in sec- 
tion 2.25-OH-D,-26,234actone produced in vitro was isolated 
and purified by high-pressure liquid chromatography using 
2 solvent systems. The amounts of 25-OHD,-26,23-lactone 
were quantitated by comparison with a standard curve made 
with authentic 25GH-D,-26,23_lactone 
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Thus, the stereochemistry of the biosynthesized 4. Discussion 
25OH-Ds-26,23-lactone from various vitamin D3 
metabolites was definitely determined to be 23@)25(R) This report demonstrates that the 25.OH-Ds-26, 
25OH-Ds-26,23-lactone. 
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Fig.2. High-pressure liquid chromatographic profiles of dia- 
stereoisomers of synthetic 25-OH-D,-26,23-lactone and bio- 
synthetic 25-OH-D,-26,23-lactone: (A) synthetic 25-OH- 
D,-26,23-lactones; (B) biosynthetic 25-OH-D,-26,23-lactone 
from 23,25,26-(OH),D,. 25eH-Ds-26,23-lactones were sub- 
jected to high-pressure liquid chromatography with a 4.6 X 
250 mm Zorbax Sil column eluted with 9% isopropanol in 
nhexane at 1 ml/min. 
23-lactone was not produced from 25(,S)26-(OH),D, 
but from 23,25-(OH)2Ds via 23,25,26-(0H)sDs (fig.1). 
The stereochemical configuration of enzymically 
synthesized 25-OH-Da-26,23-lactone from 23,25- 
(OH)2D3 and 23,25,26-(0H)aDs was 23(S)25@) at 
C-23 and C-25 positions (fig.2). Therefore, the stereo- 
chemistry of isolated 23,25-(0H)sDs and 23,25,26- 
(OI-I)sDs from the serum of rats was determined 
unequivocally to be 23(S)25-(OI-&D, and 23(,.9)25(R)- 
26-(OI&Ds, respectively. Natural 25,26-(0H)sDs 
was reported to possess the 23(S) absolute configura- 
tion [15-l 71. With 25(S)26-(OH)2D, as an inter- 
mediate in the biosynthesis of the lactone, the stereo- 
chemical inversion of hydroxy-group at C-25 position 
should occur during the course of lactone formation. 
The production of 25-OH-D3-26,23-lactone from 
23,25,26-(0H)sDs was 16 &times more than that 
from 23,25-(OH)zDs. In [ 181 23(S)25-(OH)2D3 was 
reported as a far better substrate for production of 
25-OH-Da-26,23-lactone than is 25,26-(0H)sDs [181. 
Thus, it might be reasonable toconsider that an oxida- 
tion reaction such as hydroxylation takes place ini- 
tially on methylene group at C-23 position, followed 
by oxidation of methyl group at C-26 position. In 
short, the 25-OH-Ds-26,23-lactone was biosynthesized 
from 25-OH-D3 by way of 23@)25-(OH)sDs to 23(S)- 
25@)26-(OH),D,. 
The biological and physiological functions of the 
25-OH-D3-2623~lactone are under investigation. 
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